Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
December 04 2023 - 3:35PM
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the
Company”), a biotechnology company dedicated to developing disease
modifying treatments for neurodegenerative diseases, will be
hosting an investor webcast on Wednesday, 6 December 2023 in
Australia / Tuesday, 5 December 2023 in the United States. Details
are listed below and registration is required.
The call will be hosted by Alterity’s CEO Dr.
David Stamler who will discuss the ATH434 efficacy data in primates
released today along with recent clinical progress.
Webcast details |
|
|
|
AUSTRALIA PARTICIPANTS: |
|
Date: |
Wednesday, 6 December 2023 |
|
Time: |
9:00 a.m. AEDT (Sydney/Melbourne) |
|
|
|
UNITED STATES PARTICIPANTS: |
|
Date: |
Tuesday, 5 December 2023 |
|
Time: |
2:00 p.m. Pacific Time |
|
|
5:00 p.m. Eastern Time |
Register for the Zoom
webcast:https://us02web.zoom.us/webinar/register/WN_9Lv1OWMtSSSqdJrRsKRiTA#/registrationRegistration
is required and dial in details will be sent directly upon
registration.
Investors will have the opportunity to ask questions during the
call, at the conclusion of the presentation. Investors are also
able to submit questions in advance to Hannah Howlett at
we-aualteritytherapeutics@we-worldwide.com
About Alterity Therapeutics
Limited
Alterity Therapeutics is a clinical stage
biotechnology company dedicated to creating an alternate future for
people living with neurodegenerative diseases. The Company’s
lead asset, ATH434, has the potential to treat various Parkinsonian
disorders and is currently being evaluated in two Phase 2 clinical
trials in Multiple System Atrophy. Alterity also has a broad drug
discovery platform generating patentable chemical compounds to
treat the underlying pathology of neurological diseases. The
Company is based in Melbourne, Australia, and San Francisco,
California, USA. For further information please visit the Company’s
website at www.alteritytherapeutics.com.
Authorisation & Additional
informationThis announcement was authorized by David
Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
AustraliaHannah
Howlettwe-aualteritytherapeutics@we-worldwide.com+61 450 648
064
U.S.Remy Bernardaremy.bernarda@iradvisory.com
+1 (415) 203-6386
Alterity Therapeutics (NASDAQ:ATHE)
Historical Stock Chart
From Apr 2024 to May 2024
Alterity Therapeutics (NASDAQ:ATHE)
Historical Stock Chart
From May 2023 to May 2024